Iambic Therapeutics IPO: $150M Raise, ~$758M Valuation, and the AI Drug Discovery Pipeline Behind IAM1363

Iambic Therapeutics set terms for a $150 million Nasdaq IPO on October 8, 2026 — 9.375 million shares at $15 to $17 apiece, implying a roughly $758 million market cap and a deal about 50% larger than the ~$100 million it was originally seeking, according to the company's amended S-1 filing. The offering hasn't priced; it's expected to do so next week.

Iambic Therapeutics IPO: The Terms So Far

Iambic Therapeutics filed an amended S-1 on October 8, 2026 setting terms for its Nasdaq IPO: 9.375 million shares priced at $15.00 to $17.00 apiece, with underwriters holding a 30-day option to buy up to 1.406 million additional shares. At the midpoint, that implies a $150 million raise and a roughly $758 million market cap.

J.P. Morgan, Jefferies, BofA Securities, and Citigroup are joint book-runners on the deal, which would list on the Nasdaq Global Select Market under the ticker IAM. The offering is still contingent on Nasdaq approving the listing and is expected to price next week, meaning every figure here is a negotiating range, not a closed deal.

Who's Anchoring the Deal

ARK Investment Management and Duquesne Family Office have both indicated non-binding interest in buying up to $60 million of shares combined at the IPO price — a notable anchor commitment for a biotech that is still well short of profitability. Those indications aren't binding orders, but they give the deal a visible demand floor before the roadshow even starts.

Iambic reported a $77.3 million net loss in 2025 against just $9.4 million in collaboration revenue, underscoring how heavily the company has leaned on pharma partnerships — including ties to Nvidia and Qatar-linked backers noted in its original September filing — rather than product revenue to fund its pipeline. The company plans to use the roughly $135 million in expected net proceeds (about $155.9 million if underwriters exercise their option in full) to advance its lead candidate and earlier-stage programs.

What Iambic Is Actually Building

Iambic was founded in 2019 as Entos and is based in San Diego, California. It has raised roughly $461.8 million since founding from backers including Nvidia, Qatar's sovereign wealth fund (QIA), Catalio, Nexus Ventures, and Coatue Management, and holds pharma partnerships with Takeda, Lundbeck, Revolution Medicines, Jazz Pharmaceuticals, Bayer, and — announced the same day as its original September filing — AbbVie, according to Reuters' reporting on the September 21, 2026 filing, carried by The Star.

Iambic's lead candidate, IAM1363, is an oral HER2 inhibitor currently in an ongoing Phase 1/1b basket trial for patients with HER2-altered solid tumors, with a registrational trial that could start as early as 2027. Two earlier-stage candidates sit behind it: IAM217, a KIF18A allosteric inhibitor whose IND was submitted to the FDA on September 30, 2026, and IAM-C1, a CDK2/4 dual inhibitor with an IND expected in Q4 2026 — both pending regulatory clearance before Phase 1/2 trials can begin.

Iambic markets itself as an AI-native drug-discovery company, positioning its computational platform against both traditional biotech R&D and a growing cluster of AI-first drug companies that have raised large private rounds over the past two years. The table below compares Iambic's IPO terms to recent peers in that category.

Sources: SEC EDGAR, and our own reporting on ADARx and Chai Discovery, checked October 9, 2026.

What the headline misses

Every number here is a negotiating range, not a signed deal. Iambic's own S-1 is a preliminary prospectus, meaning the $15-$17 price, the 9.375 million share count, and the resulting $758 million valuation can all still move before the offering actually prices next week. ARK and Duquesne's combined $60 million of indicated interest is also explicitly non-binding — a cleaner signal of real demand will be whether those orders actually convert at the top of the range once the book closes.

The business itself carries real pre-revenue risk. A $77.3 million net loss against $9.4 million in collaboration revenue means Iambic is years away from its own product revenue, and its lead candidate IAM1363 is still in an early basket trial — a registrational trial isn't expected to start before 2027 at the soonest. Investors here are pricing a drug-discovery pipeline, not an approved therapy.

Context also matters for the deal's reception: this quarter's broader biotech IPO pipeline has produced far more S-1 filings than actual pricings, meaning Iambic is debuting into a market that has been more willing to file than to buy. A $150 million deal that prices above range would be a real signal about investor appetite for AI-native biotech specifically; one that prices at the bottom or gets pulled would say the opposite.

Is the Deal Size Increase a Good Sign?

Going from a placeholder ~$100 million target in September to priced terms implying $150 million in October, with two large institutional names attached as non-binding anchors, is a meaningfully stronger position than Iambic was in three weeks earlier. That's real progress, not just paperwork — amended S-1s with firm price ranges and named anchor investors typically come after banks have already tested demand with institutional investors.

Whether that translates into a durable public-market valuation is a separate question that won't be answered until IAM actually starts trading. A $758 million implied cap on a company with a single Phase 1/1b asset and no near-term path to revenue is a bet on Iambic's AI-discovery platform generalizing to a broader pipeline — the same bet every AI-native biotech is asking public investors to make, just with less dilution risk than Iambic's earlier private backers took on.